Skip to Content

MYPAID 90MG SR TABLETS

Active substance(s): DIHYDROCODEINE TARTRATE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Mypaid 90mg SR Tablets.

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 90mg dihydrocodeine tartrate.
For excipients, see section 6.1.

3

PHARMACEUTICAL FORM
Prolonged-release tablets.
Round, flat, white to off-white tablets.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
For the relief of severe pain in cancer and other chronic conditions.

4.2

Posology and method of administration
Oral
The tablets should not be chewed.
Adults and children older than 12 years: 60 mg - 120 mg every 12 hours.
Elderly: Dosage should be reduced.
Children up to 12 years: Not recommended.

4.3

Contraindications
Hypersensitivity to dihydrocodeine or any of the excipients.
Respiratory depression, obstructive airways disease.
As dihydrocodeine may cause the release of histamine, it should not be given during
an asthma attack.
Avoid in acute alcoholism and where there is a risk of paralytic ileus.
Opioid analgesics should not be administered to patients with increased intracranial
pressure and head injury.
Avoid concomitant use with and for 2 weeks after stopping MAOIs

4.4

Special warnings and precautions for use
Caution should be exercised in hypotension, hypothyroidism, asthma (see 4.3),
decreased respiratory reserve, prostatic hypertrophy and convulsive disorders. Severe
withdrawal symptoms may occur in dependent patients if treatment is withdrawn
abruptly.
The dose should be reduced in elderly and debilitated patients. Reduce dose or avoid
in hepatic or renal function impairment.

4.5

Interaction with other medicinal products and other forms of interaction
Opioid analgesics may interact wth the following:
Alcohol - enhanced hypotensive and sedative effects
Antidepressants, Tricyclic - sedative effects possibly increased
Antipsychotics - enhanced hypotensive and sedative effects
Anxiolytics and Hypnotics - increased sedative effect
Cimetidine - metabolism of opioid analgesics inhibited by cimetidine
(increased plasma concentration)
Ciprofloxacin - avoid premedication with opioid analgesics (reduced plasma
concentration of ciprofloxacin) when ciprofloxacin used for surgical
prophylaxis.
Domperidone - opioid analgesics antagonise effects of domperidone on gastrointestinal activity
MAOIs - possible CNS excitation or depression (hypertension or hypotension)
when opioid analgesics given with MAOIs —avoid concomitant use and for 2
weeks after stopping MAOIs
Metoclopramide - opioid analgesics antagonise effects of metoclopramide on
gastro-intestinal activity.
Mexiletine - opioid analgesics delay absorption of mexiletine
Moclobemide- possible CNS excitation or depression (hypertension or
hypotension)

Ritonavir - plasma concentration of opioid analgesics (except methadone)
possibly increased by ritonavir
There is an increased risk of toxicity with myelosuppressive drugs

4.6

Pregnancy and lactation
Dihydrocodeine has been taken in pregnancy, although there is very little published
about its safety.
Third trimester: Depression of neonatal respiration; withdrawal effects in neonates of
dependent mothers; gastric stasis and risk of inhalation pneumonia in mother during
labour.
Dihydrocodeine has not been reported to be excreted in breast milk. However, it is
advisable that dihydrocodeine only be administered to breast-feeding mothers if
considered essential.

4.7

Effects on ability to drive and use machines
Dihydrocodeine may cause drowsiness: If affected, patients should not drive or
operate machinery.

4.8

Undesirable effects
Nausea and vomiting (particularly in initial stages), constipation, and drowsiness;
larger doses may produce respiratory depression and hypotension. Other side-effects
include abdominal pain, difficulty with micturition, urinary retention, ureteric or
biliary spasm, dry mouth, sweating, paraesthesia, headache, facial flushing, vertigo,
bradycardia, tachycardia, palpitations, postural hypotension, hypothermia, confusion,
hallucinations, dysphoria, mood changes, dependence, miosis, decreased libido or
potency, rashes, urticaria and pruritus.

4.9

Overdose
Opioid analgesics cause varying degrees of coma, respiratory depression, and
pinpoint pupils. The specific antidote naloxone is indicated if there is coma or
bradypnoea.
Since naloxone has a shorter duration of action than many opioids, close monitoring
and repeated injections are necessary according to the respiratory rate and depth of

coma. Where repeated administration of naloxone is required, it may be given by
continuous intravenous infusion and the rate of infusion adjusted according to vital
signs.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Pharmacotherapeutic
Dihydrocodeine

Group:

Analgesics,

Natural

Opium

Alkaloids



ATC code: NO2A AO8
Dihydrocodeine is a semisynthetic narcotic analgesic with a potency between
morphine and codeine. It acts on opioid receptors in the brain to reduce the patient's
perception of pain and improve the psychological reaction to pain by reducing the
associated anxiety.

5.2

Pharmacokinetic properties
Dihydrocodeine is well absorbed from the gastrointestinal tract following
administration and plasma levels are maintained throughout the twelve hour dosing
interval.
Like other phenanthrene derivatives, dihydrocodeine is mainly metabolised in the
liver with the resultant metabolites being excreted mainly in the urine. Metabolism of
dihydrocodeine includes o-demethylation, n-demethylation and 6-keto reduction.

5.3

Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to
that already included in other sections of the SPC.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Glyceryl behenate
Calcium sulphate dihydrate

Copovidone VA 64
Sodium stearyl fumarate

6.2

Incompatibilities
Not applicable

6.3

Shelf life
3 years

6.4

Special precautions for storage
Store below 25oC

6.5

Nature and contents of container
PVC/PVDC/Aluminium foil blister
Packs containing 56 or 60 tablets. Not all pack sizes may be marketed.

6.6

Special precautions for disposal
Not applicable

7

MARKETING AUTHORISATION HOLDER
Sandoz Limited
Frimley Business Park,
Frimley,
Camberley,
Surrey,
GU16 7SR,
United Kingdom.

8

MARKETING AUTHORISATION NUMBER(S)
PL 04416/0581

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
02/05/2006

10

DATE OF REVISION OF THE TEXT
02/05/2006

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide